Nonetheless, because CSF tau protein remains a high-cost, difficult-to-access biomarker, finding a reliable blood substrate for its measurement will be crucial in the treatment of HD, and of Alzheimer’s disease especially [57]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.